MILAN, Italy--(BUSINESS WIRE)--Vision-Sciences, Inc. (Nasdaq: VSCI) announced the international introduction of its video cystoscopy platform at the 23 rd Annual European Association of Urology (EAU) ...
The guidelines state that clinicians should offer blue light cystoscopy, if available, as an adjunct to traditional white light cystoscopy (WLC) to increase tumor detection and decrease recurrence.
Real-world study confirms the improved sensitivity of blue light vs white light cystoscopy (91% vs 79%) for detecting bladder cancer. The following article is part of conference coverage from the 2018 ...
May 13, 2011, 9:47 AM EDT / Source: GlobeNewswire ORANGEBURG, N.Y., May 13, 2011 (GLOBE NEWSWIRE) -- Vision-Sciences, Inc. (Nasdaq:VSCI) announced today the introduction by Stryker Corporation ...
Blue light cystoscopy reduces bladder cancer recurrence risk by 38% compared to white light cystoscopy, as shown in the BRAVO study. The BRAVO study used real-world data from 626 veterans, confirming ...
OSLO, Norway, March 24, 2025 /PRNewswire/ --Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces two abstract presentations at the 2025 European Association of Urology congress (EAU) in ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback